U.S. Official: U.S.-India Trade Deal Could Be Signed Within Three to Four Months
Taylor Wilson
A senior US official says a bilateral trade deal with India is three to four months from signing, but an unfinished Section 301 probe and steep new generic-drug tariffs could reshape what the deal is actually worth.
The deal is "already there" — so why hasn't it been signed?
A senior US official, speaking on the sidelines of the ASEAN foreign ministers' meeting in Manila, said negotiations are essentially complete: "The agreement is already there. We have the documents."
The holdup is not a bilateral disagreement. It is an unfinished US Section 301 investigation — a legal tool that authorizes Washington to impose tariffs or retaliatory measures over "unfair trade practices."
This means → India's timeline depends on a US internal process it cannot control. The signing clock is set in Washington, not New Delhi.
When does the 301 probe wrap up?
The official said one 301 investigation covering 60 countries is expected to conclude this week or next.
Once it closes, "you will see progress not just with India but elsewhere" — This means → the US-India deal is one of a batch of trade arrangements moving in parallel, not a standalone priority.
In plain terms = India is not in an exclusive queue. It is on a 60-country assembly line.
Generic-drug tariffs — India's deepest cut?
Trump announced that from August 1, imported generics get a two-year zero-tariff transition, after which the rate jumps to 100% — and a year later to 200%.
India is the largest source of US generic-drug imports. In 2025 its pharma exports to the US reached $9.7 billion, nearly 38% of its total $25.8 billion in pharmaceutical exports.
This means → the two-year grace period sounds generous, but a 200% end-state tariff effectively shuts the door. Indian drugmakers must find alternatives or secure exemptions before the window closes.
Can the drug tariffs be carved out inside the trade deal?
Beyond generics, the US has proposed tariffs of up to 12.5% on dozens of countries — India included — citing alleged "forced labor."
Whether the generic-drug tariffs can receive an exemption within the US-India trade deal is the key variable to watch next.
In plain terms = the deal's real value is not about whether it gets signed — it is about whether it can block the tariffs that hurt most.
Content is for reference only, not financial advice.